Preclinical activity of the antibody-drug conjugate denintuzumab mafodotin (SGN-CD19A) against pediatric acute lymphoblastic leukemia xenografts.

Luke JonesHannah McCalmontKathryn EvansChelsea MayohRaushan T KurmashevaCatherine A BillupsPeter J HoughtonMalcolm A SmithRichard B Lock

Published in: Pediatric blood & cancer (2019)

Denintuzumab mafodotin showed single-agent activity against selected B-lineage ALL PDXs, although leukemia growth was evident in most models at 28 days from treatment initiation. This level of activity for denintuzumab mafodotin is consistent with that observed in adults with ALL.

Keyphrases

acute lymphoblastic leukemia
acute myeloid leukemia
stem cells
single cell
mesenchymal stem cells
cell therapy
cancer therapy